ViGeneron is based on our passion to deliver gene therapy innovations and advances to people in need. Our proprietary science solves major limitations in current gene therapy approaches. At ViGeneron we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is b...
ViGeneron is based on our passion to deliver gene therapy innovations and advances to people in need. Our proprietary science solves major limitations in current gene therapy approaches. At ViGeneron we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two unique and proprietary adeno-associated virus (AAV) technology platforms. ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.